AMGN 10-K Analysis: Net Income Doubled While Cash Flow Fell 13%
Amgen reported $7.7 billion in net income for FY2025 — an 88.5% surge. But operating cash flow fell 13.3%, free cash flow collapsed 22%, and accounts receivable spiked 41% against just 10% revenue growth. Meanwhile, buried in the product revenue footnote: growth products overtook legacy at-risk drugs for the first time. The patent cliff narrative is partially obsolete — but a $12.3 billion debt maturity wall and negative ROIIC complicate everything.